Pilot Trial of Ondansetron in the Treatment of 8 Patients With Obsessive-Compulsive Disorder
J Clin Psychiatry 2003;64(9):1025-1030
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Method: Eight medication-free subjects
with a DSM-IV diagnosis of OCD and a Yale-Brown Obsessive
Compulsive Scale (YBOCS) score >= 16 entered an 8-week
open-label trial of ondansetron at a fixed dose of 1 mg 3 times
daily in a study conducted between February and October 1998.
Results: Six subjects completed the
trial. Three subjects (37%) achieved a clinically significant
response (>= 35% reduction in YBOCS score). For these
subjects, the average reduction in YBOCS-rated symptoms was 55%.
In aggregate, the 8 patients exhibited a 28% reduction in
YBOCS-rated symptoms over the course of the trial. The medication
was well tolerated.
Conclusion: These results suggest that
low-dose ondansetron may have promise as a monotherapy for some
patients suffering from OCD.